Merck 与 Isomorphic Labs 合作开发肿瘤药物候选物
STAT+: Merck, Isomorphic Labs partner to develop oncology drug candidates
Merck 和 Isomorphic Labs 近日宣布合作,利用后者基于诺贝尔奖技术的药物设计引擎和前者现有的湿实验室数据,共同发现针对一个战略重要肿瘤靶点的小分子药物候选物。Merck 将负责后续的临床前和临床开发、生产和商业化。
![]()
Merck and Isomorphic Labs, the artificial intelligence drug designer built on a Nobel winning technology that can model how molecules will bind to proteins, said Thursday that they are entering into a research collaboration to discover small molecule candidates for an undisclosed oncology target of “strategic importance.”
The partnership — only the latest such deal between a pharma giant and Isomorphic — will bring together the latter’s proprietary drug design engine and existing wet lab data from Merck, officials from both companies said. Merck will handle the preclinical and clinical development, manufacturing, and commercializing of any products.
“It is a target of high interest to us, a target where we have deployed internal efforts, and we think the pairing of those datasets with the Isomorphic drug discovery engine technology could be a very powerful pairing,” said George Addona, global head of discovery, preclinical development, and translational medicine at Merck.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com